Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug.

Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering drug inclisiran before they got a good look at the data – and it looks ...

NHS England says inclisiran, given as a twice-a-year injection, could save about 30,000 lives within a decade. It normally costs nearly £2,000 per dose but Novartis, which makes it, has agreed an ...

In recent years, medical advancements have led to the development of various cholesterol-lowering medications and one such breakthrough medication is Inclisiran. KEM Hospital in Mumbai is ...

Basel, December 22, 2021 — Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio ® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower ...